SCHEMBL637537

SCHEMBL637537

Cc1c(-c2ccc(O)cc2)n(Cc2ccc(O)cc2)c2ccc(O)cc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 20/20 0.72
ESR2 Q92731 5/20 0.72
MLNR O43193 1/20 0.65
ABCB11 O95342 1/20 0.65
NR3C1 P04150 1/20 0.65
CHRM2 P08172 1/20 0.65
HTR1A P08908 1/20 0.65
ADRA2A P08913 1/20 0.65
ADORA3 P0DMS8 1/20 0.65
CHRM1 P11229 1/20 0.65
DRD2 P14416 1/20 0.65
ADRA2B P18089 1/20 0.65
ADRA2C P18825 1/20 0.65
DRD1 P21728 1/20 0.65
SLC6A2 P23975 1/20 0.65
HTR2A P28223 1/20 0.65
SLC6A4 P31645 1/20 0.65
ADRA1A P35348 1/20 0.65
PTGS2 P35354 1/20 0.65
OPRM1 P35372 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23660870 0.96 ESR1 (0.68) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL22904939 0.93 ESR1 (0.65) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL24948898 0.91 ESR1 (0.63) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL25079140 0.91 ESR1 (0.64) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL23660869 0.91 ESR1 (0.72) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL26158855 0.91 ESR1 (0.63) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL27570464 0.90 ESR1 (0.62) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL26510970 0.90 ESR1 (0.64) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL22904947 0.88 ESR1 (0.64) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL15344637 0.88 ESR1 (0.82) ESR1ESR2MLNRABCB11NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104311468-A Bazedoxifene impurity synthesis method AVENTIS PHARMA HAINAN CO LTD 2015-01-28 CN claimed
WO-2018182205-A1 STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BAZEDOXIFENE ACETATE 한미약품 주식회사 2018-10-04 WO disclosed
US-20120253038-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF SANDOZ AG (CH) 2012-10-04 US disclosed
US-20120253038-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF SANDOZ AG (CH) 2012-10-04 US disclosed
US-20120253038-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF SANDOZ AG (CH) 2012-10-04 US disclosed
EP-2311805-B1 New polymorphic form of bazedoxifene acetate ZENTIVA KS (CZ) 2012-05-09 EP disclosed
EP-2419406-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF Sandoz AG (CH) 2012-02-22 EP disclosed
US-8034807-B2 Salts of bazedoxifene ZENTIVA K.S. (CZ) 2011-10-11 US disclosed
US-8034807-B2 Salts of bazedoxifene ZENTIVA K.S. (CZ) 2011-10-11 US disclosed
US-8034807-B2 Salts of bazedoxifene ZENTIVA K.S. (CZ) 2011-10-11 US disclosed
EP-2311805-A1 New polymorphic form of bazedoxifene acetate Zentiva, K.S. (CZ) 2011-04-20 EP disclosed
EP-2185510-B1 NEW SALTS OF BAZEDOXIFENE ZENTIVA KS (CZ) 2011-04-06 EP disclosed
WO-2010118997-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF SANDOZ AG (CH) 2010-10-21 WO disclosed
WO-2010118997-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF SANDOZ AG (CH) 2010-10-21 WO disclosed
US-20100240888-A1 SALTS OF BAZEDOXIFENE ZENTIVA K.S. (CZ) 2010-09-23 US disclosed
US-20100240888-A1 SALTS OF BAZEDOXIFENE ZENTIVA K.S. (CZ) 2010-09-23 US disclosed
US-20100240888-A1 SALTS OF BAZEDOXIFENE ZENTIVA K.S. (CZ) 2010-09-23 US disclosed
EP-2185510-A2 NEW SALTS OF BAZEDOXIFENE Zentiva, K.S. (CZ) 2010-05-19 EP disclosed
WO-2009012734-A2 NEW SALTS OF BAZEDOXIFENE ZENTIVA A.S. (CZ) 2009-01-29 WO disclosed
WO-2009012734-A2 NEW SALTS OF BAZEDOXIFENE ZENTIVA A.S. (CZ) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240888-A1 SALTS OF BAZEDOXIFENE CYP19A1, SHBG, NR5A1 ESR1 4/4885ESR2 8/4885MLNR 1707/4885
US-20120253038-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF CYP19A1, HSD17B11, CYP2F1 ESR1 4/4885ESR2 20/4885MLNR 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.